The clinical efficacy of autologous vein wrapping for recurrent compressive neuropathy has been demonstrated; however, the underlying mechanisms of this technique remain unclear. Rats were divided into chronic constriction injury (CCI) and CCI þ vein wrapping (CCI þ VW) groups. Mechanical allodynia was evaluated using von Frey filaments. To identify the neuroprotective factors released from veins, basic fibroblast growth factor (bFGF) mRNA expression in veins was compared to that in the sciatic nerve. The response of heme oxygenase-1 (HO-1) expression to vein wrapping was evaluated by RT-PCR and enzyme-linked immunosorbent assays. The effects of exogenous bFGF on HO-1 expression were evaluated using a sciatic nerve cell culture. Vein wrapping significantly increased the withdraw threshold levels compared to the untreated CCI group. bFGF mRNA expression in veins was higher than that in untreated sciatic nerves. HO-1 mRNA expression was induced at higher levels in sciatic nerve cells in the presence of exogenous bFGF compared to untreated control cells. HO-1 mRNA and protein expression in the sciatic nerve were also higher in the CCI þ VW group compared with the CCI group. Our results suggest that vein-derived bFGF contributes to the therapeutic benefit of vein wrapping through the induction of HO-1 in the sciatic nerve. Vein wrapping is a useful technique for reducing neuropathic pain. Further understanding of the neurotrophic factors released from veins may help to optimize current procedures for treating recurrent compressive neuropathy and traumatic peripheral nerve injury, and lead to the development of new therapeutic methods using recombinant neurotrophic factors. Protecting and isolating nerves from the surrounding tissues during peripheral nerve surgery can improve outcomes by reducing fibrosis and decreasing adhesion to surrounding scar tissue.
Protecting and isolating nerves from the surrounding tissues during peripheral nerve surgery can improve outcomes by reducing fibrosis and decreasing adhesion to surrounding scar tissue. 1 The technique of using autologous veins as a protective material is called "vein wrapping." Masear et al. 2 first reported the successful use of vein wrapping for reducing recurrent symptoms secondary to nerve scarring. Several basic and clinical studies have shown that in patients with recurrent compressive neuropathy, such as carpal tunnel, cubital tunnel, radial tunnel, and tarsal tunnel syndromes, and traumatic peripheral nerve injury, vein wrapping improves nerve function and the symptoms associated with these disorders. [3] [4] [5] [6] [7] [8] [9] [10] However, despite the therapeutic potential of autologous vein wrapping, the underlying mechanisms of this technique have not been resolved.
During the early phase of peripheral nerve injury, the heparin-binding protein basic fibroblast growth factor (bFGF) has neuroprotective effects and contributes to the proliferation of undifferentiated Schwann cells and nerve regeneration. [11] [12] [13] [14] [15] [16] Venous endothelial and smooth muscle cells contain large quantities of bFGF. [17] [18] [19] In venous-venous bypass grafts, the release of bFGF from veins inserted into the arterial circulation is markedly increased. 20 Based on these findings, we speculated that vein wrapping exerts neuroprotective effects through the elevated release of bFGF.
Several in vitro and in vivo studies have demonstrated that anti-oxidants relieve neuropathic pain resulting from peripheral nerve injury. [21] [22] [23] For example, heme oxygenase-1 (HO-1) is a rate-limiting enzyme that catalyzes the oxidative degeneration of heme into biliverdin, carbon monoxide, and iron. HO-1 over-expression or induction is associated with potent anti-inflammatory and antinociceptive effects, both in vitro and in mice, [24] [25] [26] [27] and also alleviates neuropathic pain induced by sciatic nerve injury. 21, 25, [28] [29] [30] A recent study reported that bFGF induces HO-1 expression in spinal cord astrocytes in vitro. 31 We therefore hypothesized that the release of bFGF by veins contributes to neuroprotection via the induction of HO-1 in injured sciatic nerves.
Here, we investigated the regulation of HO-1 by bFGF in the sciatic nerve after vein wrapping using a rat chronic constriction injury (CCI) model.
Use of Laboratory Animals (1996 Revision). Eight-week-old male Wistar rats (n ¼ 140) weighing 240-260 g were used in this study. The rats were housed in a semi-barrier system with a controlled environment (lighting, 12-h light/dark cycle; temperature, 21-23˚C; humidity, 45-65%) throughout the study. All rats were fed a diet of standard rodent chow (CRF-1; Oriental Yeast Co., Ltd., Tokyo, Japan).
We generated a sciatic nerve injury model by CCI of the sciatic nerve, as described by Bennett and Xie. 32 Briefly, rats were anesthetized with a combination of ketamine hydrochloride (100 mg/kg) and xylazine hydrochloride (10 mg/kg). The biceps femoris and gluteus superficial muscles were separated, and the right sciatic nerve was exposed. CCI was produced by loosely tying four ligations around the sciatic nerve at 1-mm intervals under a microscope. The ligatures were tightened until a brief twitch was elicited in the respective hind limb. 33 The vein graft harvested from one donor rat was used for the vein wrapping procedures of three rats.
Rats were randomly divided into three groups. In the sham group (n ¼ 39), rats underwent exposure and decompression for suturing around the right sciatic nerve only. In the CCI group (n ¼ 42), rats underwent surgery to produce CCI. In the vein-wrapping group (n ¼ 42), rats underwent the vein wrapping procedure after CCI surgery (CCI þ VW group). Vein grafts were harvested from the abdominal portion of the vena cava of donor rats 34 and were then used to wrap the ligated sciatic nerve, with the endothelial surface adjacent to the epineurium of the nerve, as described by Masear et al. 
Behavioral Tests
Six rats from each experimental group were exclusively used for behavioral testing. The rats were randomized and acclimated to the test chamber for 1 h before performing the behavioral tests. Baseline thresholds were obtained 3 days before surgery. The behavioral testing was performed at 1, 3, 5, 7, and 14 days after surgery.
Mechanical allodynia was assessed by probing the hind paw with non-noxious graded stimuli (Mono-filament Kit; Smith & Nephew, Germantown, WI) applied perpendicularly to the plantar surface of the paw through wire-mesh observation cages. The paw withdrawal threshold was determined by sequentially increasing and decreasing the stimulus strength, and withdrawal data was then analyzed using the Dixon nonparametric test, 35 as described by Chaplan et al.
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bFGF and HO-1mRNA Expression Analysis Five untreated rats were exclusively used for the analysis of bFGF mRNA expression in sciatic nerves and veins. After the rats were anesthetized as described above, the sciatic nerve and vena cava were immediately removed.
For the analysis of HO-1 mRNA expression in the sciatic nerve, five rats in each experimental group were anesthetized and the ligated right sciatic nerve was resected before (untreated rats), and 1, 3, 5, 7, and 14 days after surgery. The resected nerves were separated from scar tissue, vein grafts, and ligatures.
Total RNA was extracted from the sciatic nerve and vein samples using Trizol reagent (Invitrogen, Carlsbad, CA) according to the manufacturer's protocol. First-strand cDNA synthesis was performed using Superscript III (Invitrogen) with total RNA as the template. Quantitative RT-PCR was then conducted with the obtained cDNA using gene-specific rat primers (Table 1) . bFGF and HO-1 primers were designed using Primer Blast software (National Center for Biotechnology Information, Bethesda, MD). Melt curve analysis was performed to confirm the specificity of the amplified products. Other primers were designed based on primer sequences reported in the literature. All primers were purchased from Hokkaido System Science Co., Ltd. (Sapporo, Japan). The PCR reaction mixture consisted of 2 ml cDNA, the specific primer set (0.2 mM final concentration), and 12.5 ml SYBR Premix Ex Taq (Takara, Kyoto, Japan) in a final volume of 25 ml. Quantitative PCR was performed using a real-time PCR Detection System (CFX-96; Bio-Rad, CA). The PCR cycle parameters consisted of an initial denaturation step at 95˚C for 1 min, followed by 40 cycles of 95˚C for 5 s, and 60˚C for 30 s. mRNA expression was normalized to the level of glyceraldehyde dehydrogenase (GAPDH) mRNA. HO-1 mRNA expression levels were compared with untreated rat (treated rats/untreated rats).
Enzyme-Linked Immunosorbent Assay (ELISA)
To examine HO-1 protein expression in the sciatic nerve, eight rats from each experimental group were used for analysis, which was performed 5 days after surgery. For the expression analysis, resected nerves were removed and separated from scar tissue, vein grafts, and ligatures, and were then immediately frozen in liquid nitrogen, followed by homogenization in CelLytic MT Lysis buffer (Sigma, St. Louis, MO) supplemented with protease inhibitor cocktail (Roche, Basel, Switzerland). HO-1 concentration in the sciatic nerve was measured using an HO-1 ELISA kit (Enzo Life Science, Switzerland). The total amount of protein in the collected nerve samples was measured using a BCA kit (Thermo Fisher Scientific Inc., Rockford, IL), and HO-1 levels were normalized to the total amount of protein.
Cell Isolation From Non-Treated Rat Sciatic Nerve
Four untreated rats were anesthetized, and bilateral sciatic nerve fragments with a length of approximately 30 mm were collected. The sciatic nerves were washed with 25 ml culture medium, which consisted of Dulbecco's Modified Essential Medium (DMEM)/F-12 supplemented with 10% fetal calf serum and penicillin-streptomycin, and the epineurium was then removed using fine forceps. Nerves were cut into 1-mm pieces and resuspended in an enzyme mixture consisting of 250 U/ml type I-S hyaluronidase (Sigma) and 160 U/ml type 1 collagenase. After 18 h of incubation at 37˚C, the nerve tissue pieces were gently triturated using a 10-ml glass pipette until the pieces could be readily drawn into a syringe. The trituration was repeated using a 22-gauge needle, followed by a 27-gauge needle. The resulting suspension was centrifuged at 300g for 5 min. After resuspension in 10 ml culture medium, the sample was again triturated using a 27-gauge needle. The resulting cell suspension was washed twice in 10 ml culture medium, with centrifuging of the sample at 300g for 5 min being performed after each wash. Finally, the washed cells were plated at a sub-confluent concentration in culture medium on poly-L-ornithine/laminin-coated six well plates (BD Biosciences), which were then incubated at 37˚C, 5% CO 2 and >95% humidity for 24 h.
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Effect of bFGF on HO-1 Expression of Sciatic Nerve Cells
Cells isolated from rat sciatic nerves, as described above, were cultured in poly-L-ornithine/laminin-coated six-well plates. After a 1-week incubation at 37˚C in a 5% CO 2 incubator, cells were incubated with 0 (control group) or 0.1 or 1 ng/ml human recombinant bFGF (Kaken Pharmaceutical Co., Ltd., Tokyo, Japan) for 2 h. The treated and control cells were harvested for total RNA isolation and HO-1 expression analysis by RT-PCR.
Immunohistochemistry
To investigate the localization of bFGF in veins and the sciatic nerve and the expression site of HO-1 in the sciatic nerve, immunohistochemistry was performed. At 5 days after surgery, three untreated rats were used for bFGF localization and three rats from the CCI and CCI þ VW groups were used for HO-1 localization. The paraformaldehyde-fixed vein and sciatic nerve tissues samples were embedded in paraffin and sliced into 4-mm thick sections. The sciatic nerve sections were cut at the center to avoid the ligatures. The sections were immunohistochemically stained with rabbit polyclonal primary antibody against bFGF (1:3000; Santa Cruz Biotechnology, Dallas, TX), mouse monoclonal antibody against HO-1 (1:250; Abcam, Cambridge, UK), and rabbit polyclonal antibody against S-100 protein (1:2500; Leica-Novocastra, Newcastle upon Tyne, UK) using peroxidase-based staining with 3,3'-diaminobezidine (DAB) to give a brown reaction product. Counter staining was performed with hematoxylin. The sections were examined by using a light microscope. Areas stained with S-100 protein were recognized as the nerve bundle. The cross-sectional area of the nerve bundle were calculated using WinROOF Ver.7.2 (Mitani Shoji, Fukui, Japan) and HO-1-immunoreactive (IR) cells in the nerve bundle were counted at 400Â magnification using counter grid. The number of HO-1 IR cells per 1 mm 2 area were calculated and compared with the CCI and CCI þ VW groups.
Statistical Analyses
All statistical analyses were performed using SPSS software (version 19.0; SPSS Inc., Chicago, IL). The Mann-Whitney U test was used to examine differences in bFGF mRNA expression between the sciatic nerves and veins. Tukey's multiple comparison tests were used to examine differences among the sham, CCI and CCI þ VW groups. The MannWhitney U test was also used to examine differences between the CCI and CCI þ VW groups in histological analysis. A p value of <0.05 was considered statistically significant.
RESULTS
Behavioral Tests
In the von Frey test, rats in the CCI group displayed significant mechanical allodynia 1 day after surgery compared with the sham group (p < 0.05). Allodynia persisted for up to 14 days after surgery. The withdraw threshold level in the CCI þ VW group was significantly increased compared to that in the CCI group from days 3 to 5 after surgery (p < 0.05; Fig. 1 ).
bFGF mRNA Expression and Localization in Veins
The endothelial surface of veins, in which cells are sparse, is relocated adjacent to the epineurium of the nerve by the vein wrapping procedure. To investigate the localization of bFGF expression in vein, immunohistochemical analyses were performed. Immunohistochemistry analysis revealed that bFGF-positive cells in veins mainly existed in the tunica media and tunica adventitia. Cells were sparsely stained within a small region of the tunica intima ( Fig. 2A) . bFGF-positive cells also present in the sciatic nerve were sparsely stained (Fig. 2B) . However, bFGF mRNA expression in veins was fivefold higher than that in the sciatic nerve (p < 0.05; Fig. 2C ).
Effect of bFGF on Expression of HO-1 in Sciatic Nerve Cell Culture
As bFGF stimulates HO-1 expression in spinal astrocytes, 31 real-time PCR was used to examine the regulation of HO-1 by bFGF in sciatic nerve cells (Fig. 3) . Expression of the HO-1 gene increased two fold in sciatic nerve cells in the presence of exogenously added bFGF (1 ng/ml) compared to untreated control cells (p < 0.05).
Expression and Localization of HO-1 in Sciatic Nerves
To investigate the possible increase of HO-1 induced by vein wrapping in vivo, HO-1 mRNA, and protein expression were examined after CCI injury with or without vein wrapping. Quantitative RT-PCR conducted on sciatic nerves from the CCI and CCI þ VW groups showed that HO-1 mRNA was significantly increased compared to the sham group 1-14 days after surgery (p < 0.05; Fig. 4) . Notably, the application of vein wrapping after CCI resulted in a further and significant elevation of HO-1 mRNA expression compared to the CCI group at 3 and 5 days after surgery (p < 0.05). The increase in HO-1 mRNA expression induced by vein wrapping was most significant on day 5 after surgery (p < 0.01; Fig. 4) .
Based on the HO-1 mRNA expression results, HO-1 protein expression in the sciatic nerve was analyzed at day 5. Compared to the sham group, HO-1 protein levels were significantly higher in the CCI and CCI þ VW groups (p < 0.05). HO-1 protein levels in the CCI þ VW group were significantly increased The S100 protein-positive region was regarded as the region of a nerve bundle (Fig. 6A and D) . The crosssectional areas of nerve bundles did not differ between the CCI and CCI þ VW groups (CCI, 411,627 AE 45,617 um 2 ; CCI þ VW, 398,029 AE 59,160 um 2 , p ¼ 0.827) There were virtually no HO-1 IR cells in the CCI group (Fig. 6B and   C) . In contrast, HO-1 IR cells were observed in nerve bundles in the CCI þ VW group (19.7 AE 5.5 cells/mm 2 , Fig. 6E and F) .
DISCUSSION
In this study, investigating the mechanisms underlying the positive therapeutic effects of vein wrapping for recurrent compressive neuropathy and traumatic peripheral nerve injury, RT-PCR revealed that bFGF was expressed at significantly higher levels in veins compared to the sciatic nerve. In addition, exogenous bFGF-induced HO-1 expression in sciatic nerve cells. Consistent with the real-time PCR and ELISA results, immunohistochemistry analysis showed that the application of vein wrapping increased HO-1 in sciatic nerve fiber bundles. Taken together, these findings suggest that bFGF from veins is one of the biological mechanisms that contributes to the therapeutic benefit of vein wrapping through the induction of HO-1 expression in the sciatic nerve.
Several clinical studies have demonstrated promising results, including the reduction of allodynia, using the vein wrapping technique for the treatment of recurrent compressive neuropathy and traumatic peripheral nerve injury. [3] [4] [5] [6] [7] [8] [9] [10] Previous experiments by our group in a rat model revealed that vein wrapping after CCI decreased pain-associated behavior and nerve damage. 34 Here, vein wrapping also inhibited the development of allodynia following CCI. To determine the mechanism underlying the therapeutic benefit of peripheral vein wrapping, Chou et al. 38 performed histopathologic analysis of biopsy specimens harvested from a carpal tunnel syndrome patient who underwent vein wrapping and provided evidence that local factors originating from the vein graft directly restored or optimized the function of the injured nerve; however, the local factors were not identified. Here, bFGFpositive cells were observed in the endothelial surface and bFGF mRNA expression in veins was fivefold higher than that in the sciatic nerve. Several recent studies demonstrated that the application of exogenous bFGF with a carrier-mediated controlled release system facilitated nerve regeneration in transected rat sciatic nerves. 13, 14, 16 For example, Fujimoto et al. 14 used electron microscopy to examine the in vivo bFGF treatment of rat sciatic nerves and found that regenerating axons grew 1.5-2-fold faster when nerve stumps were treated with bFGF compared with phosphatebuffered saline. In a previous study, we revealed that the application of vein wrapping after CCI promoted axon growth, myelination, nerve arrangement, and Schwann cell nucleation, and less nerve degeneration compared to CCI alone. 34 Based on these findings, the release of vein-derived bFGF at graft sites may play be important for the therapeutic effect of vein wrapping.
HO-1 expressed at sites of rat sciatic nerve injury in the peripheral nervous system may contribute to cellular adaptive function when cells have lost contact with axons, and appears to play a crucial role in nerve regeneration. 39 Upregulation of HO-1 in Schwann cells may also enhance neuroprotection. 40 Here, bFGF stimulated HO-1 expression in sciatic nerve cells, as was previously reported in spinal astrocyte culture. 31 We also demonstrated that vein wrapping further stimulated HO-1 expression in sciatic nerve tissue. Sciatic nerve contains several cell types, including Schwann cells, fibroblasts, macrophages, perineural cells, pericytes, endothelial cells, mast cells, and some classes of progenitor cells. [41] [42] [43] [44] [45] In present study, the mechanism of increase of HO-1 expression in response to bFGF in specific cells of sciatic nerve were not determined; however, previous findings, taken together with our present results, suggest that bFGF derived from veins exerts a neuroprotective effect via the induction of HO-1 in injured sciatic nerves.
Vein wrapping improved the withdraw threshold 3-5 days after CCI; however, both HO-1 mRNA expression level in sciatic nerve and the withdraw threshold level of the CCI þ VW group decreased almost to almost the same degree as in the CCI group only 14 days after surgery. Our preliminary study showed that bFGF expression in vein gradually decreased after vein wrapping (data not shown). On this basis, we suggest that while vein wrapping induced-HO-1 expression in the early phase, it may have had limited efficacy in the late phase.
Several limitations of this study warrant mention. First, veins harvested from other rats are not autografts. We previously used veins harvested from another rats as a vein wrapping model, and therefore used the same model in this study. However, to mimic autografts, inbred rats may be more suitable than a closed colony. Second, although we found that exogenously added recombinant bFGF stimulated HO-1 expression in sciatic nerve cultures, several authors have reported that bFGF exerts neuroprotective effects via a reduction in inflammatory cytokine release 46 or nitric oxide-induced cell death. 47 It remains to be determined whether bFGF induces other pathways which contribute to the relief of allodynia following vein wrapping. Finally, we revealed that HO-1 expression was elevated in the CCI þ VW group; however, it remains unclear if the elevation of HO-1 levels contributes to the attenuation of allodynia.
In conclusion, the present findings suggest that vein-derived bFGF may contribute to the therapeutic efficacy of vein wrapping through the induction of HO-1 expression. This finding may lead to the development of new therapeutic targets for treating neuropathic pain caused by recurrent compressive neuropathy or traumatic peripheral nerve injury.
